Yuliia Borysovych

Yuliia Borysovych

Auto-generated profile, based on publicly available information

Yuliia Borysovych

Immune Modulation in Cancer German Cancer Research Center (DKFZ) Heidelberg Germany

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2026 in medRxiv
Verified
Preprint
Open access
PDF file
VBVitalina Bashinskaya
Vitalina Bashinskaya
OZOksana Zahorodnia
Oksana Zahorodnia
YBYuliia Borysovych
Yuliia Borysovych
YZYaroslav Zaplatnikov
Yaroslav Zaplatnikov
VVValeriia Vasylieva
Valeriia Vasylieva
Marika KaakinenMarika Kaakinen
Marika Kaakinen
Background: Substance use disorders (SUDs), including alcohol and drug dependence, and smoking, pose a public health threat with their high prevalence and comorbidity with other diseases, and contribution to mortality. SUDs are highly correlated, and their genetic background is shared to some degree. Objectives: We aimed to investigate the genetic associations of previously reported loci for a wide range of SUDs in an unstudied Ukrainian population. Methods: We collected data from 595 individuals (339 women, 253 men), including 321 participants from two rehab centres. Based on clinical review and questionnaire data we defined drug dependence, alcohol dependence, alcohol abuse, binge drinking, smoking, opiate, amphetamine, cannabis, and hallucinogen use, along with several intermediary alcohol use and smoking variables considering the amount of use and the level of dependence. We genotyped COMT -rs4680, ADH1B-ADH1C -rs1789891, and HTR2A -rs6313, and applied logistic and ordered logistic regression assuming an additive inheritance model, controlling for the recruitment group, other substance uses, age, and sex, in the association analyses. Results: We replicate ( P <0.05) the associations at COMT -rs4680 with smoking status (OR[95% CI]=1.56[1.01-2.41], P =0.047) and heaviness (1.37[1.04-1.80], P =0.026), and at ADH1B-ADH1C -rs1789891 and HTR2A -rs6313 with alcohol dependence (1.69[1.03-2.76], P =0.038 and 0.66[0.47-0.92, P =0.016], respectively). Furthermore, we provide evidence for an association at HTR2A -rs6313 with hallucinogen use (0.58[0.35-0.98], P =0.040). Conclusion: In this study on multiple SUDs we shed light on the genetic background of SUDs in Ukrainians and provide further evidence that variation at COMT is mainly associated with smoking, at ADH1B-ADH1C with alcohol-related variables, whereas HTR2A is a more general SUD-associated locus. Highlights: We present the first genetic study of substance use disorders in Ukrainians We replicate the associations at COMT -rs4680 with smoking status and heaviness, and ADH1B-ADH1C -rs1789891 and HTR2A -rs6313 with alcohol dependence We provide evidence for an association at HTR2A -rs6313 with hallucinogen use

14 September 2026 in HemaSphere
Verified
Journal Article
Open access
PDF file
HBHannah Briesch
Hannah Briesch
MCMariana Coelho
Mariana Coelho
AFAlessia Floerchinger
Alessia Floerchinger
YBYuliia Borysovych
Yuliia Borysovych
NANicolas Aubert
Nicolas Aubert
MSMartina Seiffert
Martina Seiffert
Chronic lymphocytic leukemia (CLL) exhibits marked clinical heterogeneity that cannot be fully explained by genetic alterations, underscoring the critical role of the tumor microenvironment in disease progression and therapeutic resistance. To delineate the temporal evolution of immune dysregulation in CLL, we used the Eµ‐TCL1 adoptive transfer (TCL1‐AT) mouse model combined with high‐dimensional spectral flow cytometry to longitudinally profile lymphoid and myeloid compartments. To assess the reproducibility across different disease kinetics, we analyzed seven independent TCL1‐AT cohorts generated from distinct primary tumors. CLL progression was associated with coordinated restructuring of adaptive and innate immune cell populations. Within the T‐cell compartment, early activation and effector expansion transitioned to a progressive accumulation of terminally exhausted CD8 + T cells. Concurrently, immunoregulatory populations expanded, including regulatory type 1 (Tr1)‐like CD4 + T cells, activated regulatory T cells (Tregs) and, importantly, a previously underappreciated Eomes‐expressing Treg subset. Natural killer (NK) cells exhibited transient expansion followed by differentiation and acquisition of exhaustion markers. Myeloid cell profiling revealed an expansion of immunosuppressive PD‐L1 high patrolling monocytes, mature regulatory dendritic cells (mregDCs), and phenotypic reprogramming of dendritic cells (DCs) consistent with impaired antigen presentation and promotion of T‐cell exhaustion and regulatory T‐cell subsets. Despite substantial variation in leukemia kinetics, expansion of patrolling monocytes, exhausted CD8 + T cells, and Tregs was consistently observed across all seven independent TCL1‐AT cohorts, demonstrating robust immune remodeling. Collectively, our findings demonstrate a stepwise transition toward a suppressive microenvironment involving innate and adaptive immune compartments in the Eµ‐TCL1 mouse model, providing a framework for understanding immune failure in CLL and informing strategies to restore anti‐leukemic immunity.